Hematology Frontier

The treatment landscape for multiple myeloma continues to evolve with successive advances in immune-targeted therapies. As a novel class of immunotherapeutic agents, bispecific antibodies have helped address major treatment challenges in patients with relapsed or refractory disease and have become a key focus of research in multiple myeloma. The 2026 Cross-Strait Hematology Academic Conference was held in Zhuhai, Guangdong, on August 21–22. During the meeting, Oncology Frontier – Hematology Frontier invited Professor Wenming Chen of Beijing Chao-Yang Hospital, Capital Medical University, to discuss the evolving role of bispecific antibodies in multiple myeloma, strategies for combination and sequential treatment, and the latest evidence presented at the 2026 European Hematology Association (EHA) Congress in the context of current clinical research in China. His insights offer practical guidance for the standardized, effective, and individualized use of bispecific antibodies to maximize treatment efficacy and safety for patients.

The 2026 China-France Scientific Symposium on Hematology and Immunology was held in Beijing from September 11 to 13, 2026. Building on the longstanding tradition of hematology exchanges between China and France, this year's meeting expanded its scope to the intersection of hematology and immunology, bringing together renowned experts from both countries to explore scientific advances and exchange perspectives. On this occasion, Oncology Frontier – Hematology Frontier invited Professor Li Wang from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, to discuss the treatment landscape and controversies in newly diagnosed mantle cell lymphoma (MCL). Professor Wang examined the paradigm shift in first-line MCL treatment in the era of Bruton tyrosine kinase inhibitors (BTKis) and shared valuable clinical insights into the evolving role of autologous stem cell transplantation (ASCT), treatment options for older or transplant-ineligible patients, and precision strategies for high-risk disease.

As autumn arrives and the harvest season begins, China and France are joining hands to open a new chapter of collaboration. Hosted by the Chinese Medical Doctor Association and the Chinese Society for Immunology, and organized by the Hematology Physicians Branch of the Chinese Medical Doctor Association and the National Clinical Research Center for Hematologic Diseases–Institute of Hematology, Peking University, the 2026 China-France Scientific Symposium on Hematology and Immunology was held in Beijing from September 11 to 13, 2026. During the conference, Oncology Frontier – Hematology Frontier interviewed Professor Olive Daniel of the Institut Paoli-Calmettes in Marseille, who shared in-depth insights into the key pathways for translating immune-regulatory research from basic science to clinical application, the current status and challenges of translational medicine, and the complementary strengths and prospects for collaboration between China and France in hematology and immunology.

The 2026 China-France Scientific Symposium on Hematology and Immunology was held in Beijing from September 11 to 13, 2026. Building on the longstanding tradition of China-France exchanges in hematology, this year's conference further expanded into the intersection of hematology and immunology, bringing together renowned experts in hematology and immunology from China and France to explore cutting-edge developments and exchange academic perspectives. On this occasion, Oncology Frontier – Hematology Frontier interviewed Professor Bingcheng Liu of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, who provided an in-depth analysis of the exploration of B-cell acute lymphoblastic leukemia (B-ALL) from personalized immunity to precision immunotherapy, including breakthrough advances in B-ALL immunotherapy, precision stratification strategies, and the optimal sequencing and integration of different immunotherapeutic approaches.

Platinum-based chemotherapy has historically been the standard first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC), but long-term survival outcomes have remained poor. There is an urgent clinical need for first-line regimens that offer high efficacy and sustained disease control. The EV-302 trial directly compared enfortumab vedotin plus pembrolizumab with standard platinum-based chemotherapy. Earlier interim analyses demonstrated the significant superiority of the combination over chemotherapy, reshaping international treatment guidelines.

In the golden autumn season, experts from across the Taiwan Strait gathered in Zhuhai. The 2026 Cross-Strait Hematology Academic Conference was held in Zhuhai, Guangdong, on August 21–22, bringing together hematology experts and scholars from both sides of the Taiwan Strait, as well as Hong Kong and Macao, for in-depth discussions on cutting-edge developments, clinical practice, and innovations in nursing. During the conference, Oncology Frontier – Hematology Frontier invited Ms. Huiju Tsai of National Taiwan University Hospital to share her perspectives on cross-Strait exchanges in hematology nursing, the application of digital tools in the comprehensive management of hematopoietic stem cell transplantation patients, and prospects for future collaboration in nursing between the two sides.

Transfusion medicine is an essential foundation for the diagnosis and treatment of hematologic diseases, and its underlying philosophy is undergoing a profound transformation from a “blood-centered” to a “patient-centered” approach. As the field advances standardized blood utilization and transfusion safety, how to establish a scientific blood management system and implement precision transfusion strategies remains a key clinical challenge. During the 2026 Cross-Strait Hematology Academic Conference, Oncology Frontier – Hematology Frontier invited Dr. Sheng‑Hsuan Chien of Taipei Veterans General Hospital to systematically review the evolution of transfusion medicine and practical experience from Taiwan, provide an in-depth interpretation of the core principles and precision transfusion pathways of patient blood management (PBM), and explore future directions for collaboration between the two sides of the Taiwan Strait in transfusion quality control, standardized blood utilization, and PBM system development. His insights provide valuable guidance for optimizing clinical blood management.

The “Gaobo Medical Forum—6th Clinical Application Seminar and Training Course on Autologous Hematopoietic Stem Cell Transplantation,” hosted by the National Clinical Research Center for Hematologic Diseases of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, and organized by Shanghai Zhaxin Hospital/Gaobo Medical Group and Shanghai Liquan Hospital, was held in Shanghai on August 29–30, 2026. During the meeting, Oncology Frontier – Hematology Frontier invited Dr. Su Li, Director of the Department of Hematology and Director of the Myeloma Center at Gaobo Shanghai Liquan Hospital, to discuss new advances from his team's work in immunotherapy for relapsed/refractory multiple myeloma (RRMM). Dr. Li provided an in-depth analysis of the mechanisms and clinical benefits of BCMA/GPRC5D dual-target CAR-T therapy and shared valuable clinical insights into optimizing combination treatment pathways and refining precision risk stratification.

The 2026 Chinese Society of Clinical Oncology (CSCO) Annual Meeting will be held in Jinan, Shandong, from September 16 to 19, 2026. As one of China's most important annual academic events in oncology, the CSCO Annual Meeting continues to focus on the international frontiers of oncology research and the needs of clinical practice in China. Experts and scholars from China and abroad will gather to engage in in-depth discussions on key topics including standardized diagnosis and treatment, cutting-edge innovation, and clinical research. Through guideline updates, academic presentations, continuing medical education, and other multidimensional programs, the meeting aims to facilitate the integration of the latest research findings into clinical practice.